Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20

被引:70
作者
McCraw, Dustin M. [1 ]
O'Donnell, Jason K. [2 ]
Taylor, Kenneth A. [3 ]
Stagg, Scott M. [2 ,4 ]
Chapman, Michael S. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA
[2] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA
[3] Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA
[4] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA
基金
美国国家卫生研究院;
关键词
Adeno-associated virus; Antibody; A20; Epitope; Fab'; Gene therapy; Monoclonal; AAV2 CAPSID GENE; ELECTRON-MICROSCOPY; IMMUNE-RESPONSES; RECEPTOR-BINDING; VIRAL VECTORS; FACTOR-IX; TRANSDUCTION; THERAPY; PARVOVIRUS; IDENTIFICATION;
D O I
10.1016/j.virol.2012.05.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The use of adeno-associated virus (AAV) as a gene therapy vector is limited by the host neutralizing immune response. The cryo-electron microscopy (EM) structure at 8.5 angstrom resolution is determined for a complex of AAV-2 with the Fab' fragment of monoclonal antibody (MAb) A20, the most extensively characterized AAV MAb. The binding footprint is determined through fitting the cryo-EM reconstruction with a homology model following sequencing of the variable domain, and provides a structural basis for integrating diverse prior epitope mappings. The footprint extends from the previously implicated plateau to the side of the spike, and into the conserved canyon, covering a larger area than anticipated. Comparison with structures of binding and non-binding serotypes indicates that recognition depends on a combination of subtle serotype-specific features. Separation of the neutralizing epitope from the heparan sulfate cell attachment site encourages attempts to develop immune-resistant vectors that can still bind to target cells. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 50 条
  • [41] Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach
    Havlik, L. Patrick
    Simon, Katherine E.
    Smith, J. Kennon
    Klinc, Kelli A.
    Tse, Longping, V
    Oh, Daniel K.
    Fanous, Marco M.
    Meganck, Rita M.
    Mietzsch, Mario
    Kleinschmidt, Jurgen
    Agbandje-McKenna, Mavis
    Asokan, Aravind
    JOURNAL OF VIROLOGY, 2020, 94 (19)
  • [42] Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive In Vitro Assays
    Kruzik, Anita
    Koppensteiner, Herwig
    Fetahagic, Damir
    Hartlieb, Bettina
    Dorn, Sebastian
    Romeder-Finger, Stefan
    Coulibaly, Sogue
    Weber, Alfred
    Hoellriegl, Werner
    Horling, Frank M.
    Scheiflinger, Friedrich
    Reipert, Birgit M.
    de la Rosa, Maurus
    HUMAN GENE THERAPY METHODS, 2019, 30 (02) : 35 - 43
  • [43] Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice
    van Lieshout, Laura P.
    Soule, Geoff
    Sorensen, Debra
    Frost, Kathy L.
    He, Shihua
    Tierney, Kevin
    Safronetz, David
    Booth, Stephanie A.
    Kobinger, Gary P.
    Qiu, Xiangguo
    Wootton, Sarah K.
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (06) : 916 - 925
  • [44] Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors
    Giles, April R.
    Govindasamy, Lakshmanan
    Somanathan, Suryanarayan
    Wilson, James M.
    JOURNAL OF VIROLOGY, 2018, 92 (20)
  • [45] Antibody Delivery Mediated by Recombinant Adeno-associated Virus for the Treatment of Various Chronic and Infectious Diseases
    Robert, Marc-Andre
    Gilbert, Renald
    Gaillet, Bruno
    CURRENT GENE THERAPY, 2016, 16 (06) : 363 - 374
  • [46] Reduced Immunogenicity of Intraparenchymal Delivery of Adeno-Associated Virus Serotype 2 Vectors: Brief Overview
    Hwu, Wuh-Liang
    Muramatsu, Shin-Ichi
    Gidoni-Ben-Zeev, Bruria
    CURRENT GENE THERAPY, 2022, 22 (03) : 185 - 190
  • [47] Structure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR
    Meyer, Nancy L.
    Hu, Guiqing
    Davulcu, Omar
    Xie, Qing
    Noble, Alex J.
    Yoshioka, Craig
    Gingerich, Drew S.
    Trzynka, Andrew
    David, Larry
    Stagg, Scott M.
    Chapman, Michael Stewart
    ELIFE, 2019, 8
  • [48] Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays
    Gorovits, Boris
    Azadeh, Mitra
    Buchlis, George
    Harrison, Travis
    Havert, Mike
    Jawa, Vibha
    Long, Brian
    McNally, Jim
    Milton, Mark
    Nelson, Robert
    O'Dell, Mark
    Richards, Karen
    Vettermann, Christian
    Wu, Bonnie
    AAPS JOURNAL, 2021, 23 (06)
  • [49] Prevalence of Neutralizing Factors Against Adeno-Associated Virus Types 2 in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
    Cheng, Yong
    Huang, Lvzhen
    Li, Xiaoxin
    Qi, Huijun
    Zhou, Peng
    Yu, Wenzhen
    Jiang, Yide A.
    Wadsworth, Samuel
    Scaria, Abraham
    CURRENT GENE THERAPY, 2013, 13 (03) : 182 - 188
  • [50] Detection of adeno-associated virus type 2 sequences in the human genital tract
    FriedmanEinat, M
    Grossman, Z
    Mileguir, F
    Smetana, Z
    Ashkenazi, M
    Barkai, G
    Varsano, N
    Glick, E
    Mendelson, E
    JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (01) : 71 - 78